# US 2023/0406837 A1 · Sulfamate modulators of pin1 activity and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406837 A1
- Document ID: US20230406837A1
- Status: Published application
- Kind: A1
- Application number: 18/334,385
- Filed: 2023-06-14
- Published: 2023-12-21
- Earliest claimed: 2022-06-14
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co., Ltd.
- Inventors: Nir LONDON; Rambabu Reddi
- Web page: https://patentgrep.com/patent/US20230406837A1

## CPC

- C07D 333/48: by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are Sulfamate compounds for use in modulating an activity of peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1).

## Claims

### Claim 1

A Sulfamate compound represented by the structure of Formula I:
or a pharmaceutically acceptable salt thereof;
wherein,
the represents a saturated or non-saturated bond;
Y and are each independently selected from the group consisting of O, S and NH;
each of R2 and Ra, Rb and Rc are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, or alternatively, R2 is absent when the dashed line represents an unsaturated bond;
each of R1, R3 and R4 are each independently selected from the group consisting of hydrogen, OH, any group that forms a urea, an amide, a thiourea, hydrazide or hydroxamic acid (via the nitrogen), substituted or unsubstituted linear or branched alkyl, alkenyl, alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, or R3 and R4 form together a five or six membered ring with the nitrogen;
n is 1, 2, 3 or 4;
L1 is a bond, substituted or unsubstituted linear or branched alkylene, substituted or unsubstituted linear or branched alkenylene, substituted or unsubstituted linear or branched alkynylene, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an ether group;
L2 is substituted or unsubstituted linear or branched alkylene, substituted or unsubstituted linear or branched alkenylene, substituted or unsubstituted linear or branched alkynylene, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an ether group;
W is O, S or NR5; and
R5 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl.

### Claim 2 (depends on 1)

The Sulfamate compound according to claim 1, wherein the Sulfamate compound is represented by the structure of Formula II:
or a pharmaceutically acceptable salt thereof;
wherein,
R1, R2, R3, R4, L1, L2, W, Y and Z are defined in claim 1.

### Claim 3 (depends on 1)

The Sulfamate compound according to claim 1, wherein the Sulfamate compound is represented by the structure of Formula III:
or a pharmaceutically acceptable salt thereof
wherein,
R1, R2, R3, L2 and W are defined in claim 1.

### Claim 4 (depends on 1)

The Sulfamate compound according to claim 1, wherein the Sulfamate compound is represented by the structure of Formula IV:
or a pharmaceutically acceptable salt thereof;
wherein,
R1 and R3, are as defined in claim 1.

### Claim 5 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein n is 2.

### Claim 6 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein Y and Z are each O (oxygen).

### Claim 7 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the a saturated bond.

### Claim 8 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein L1 is a bond.

### Claim 9 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R4 is a hydrogen.

### Claim 10 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein L2 is methylene.

### Claim 11 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R3 is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalicyclic, or substituted or unsubstituted heteroaryl.

### Claim 12 (depends on 11)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R3 is C1-C10 alkyl, benzyl, or substituted or unsubstituted phenyl.

### Claim 13 (depends on 11)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R3 is selected from the group consisting of C1-C3 alkyl, benzyl, or phenyl, wherein the C1-C3 alkyl of R3 is unsubstituted or substituted with halo, hydroxy, alkoxy, cyano, or oxo; and the benzyl or phenyl of R3 is unsubstituted or substituted with halo, alkyl, hydroxy, alkoxy, or cyano.

### Claim 14 (depends on 12)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 12, wherein said substituted phenyl is substituted with alkyl or halo.

### Claim 15 (depends on 11)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R3 is unsubstituted C1-C3 alkyl, unsubstituted benzyl, or phenyl, wherein the phenyl of R3 is unsubstituted or substituted with halo or C1-C3 alkyl.

### Claim 16 (depends on 11)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R3 is methyl.

### Claim 17 (depends on 11)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R3 is benzyl.

### Claim 18 (depends on 11)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R3 is phenyl, unsubstituted or substituted with halo or C1-C3 alkyl.

### Claim 19 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is represented by Formula A:
—CH2-Q′ Formula A
wherein Q′ is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino.

### Claim 20 (depends on 19)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein Q′ is a tertiary alkyl, alkenyl, alkynyl, cycloalkyl, or heterocyclic.

### Claim 21 (depends on 19)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein Q′ is a substituted or unsubstituted t-butyl or substituted or unsubstituted cycloalkyl.

### Claim 22 (depends on 19)

The sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein Q′ is C4-C6 alkyl or C5-C7 cycloalkyl, each of which is unsubstituted or substituted by halo, hydroxy, alkoxy, cyano, or oxo.

### Claim 23 (depends on 19)

The sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein the alkyl of Q′ is secondary or tertiary.

### Claim 24 (depends on 23)

The sulfamate compound or pharmaceutically acceptable salt thereof according to claim 23, wherein the alkyl of Q′ is tertiary.

### Claim 25 (depends on 19)

The sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein Q′ is tert-butyl.

### Claim 26 (depends on 19)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein Q′ is cyclohexyl.

### Claim 27 (depends on 19)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 19, wherein Q′ is a triazole.

### Claim 28 (depends on 27)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 27, wherein said triazole has Formula B:
wherein R6 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heteroalicyclic, aryl and heteroaryl.

### Claim 29 (depends on 1)

The Sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the Sulfamate compound is represented by the structure of compound:
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 1)

A method of modulating the activity of Pin1 comprising contacting Pin1 with the sulfamate compound or pharmaceutically acceptable salt thereof according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

The method according to claim 30, wherein a covalent bond is formed between Cys113 residue of said Pin1 and a carbon near the sulfamate group (electrophilic site), wherein releasing a sulfamic acid leaving group; and wherein hydrogen bonds are formed between Gln131 and His 157 residues of said Pin1 and the sulfur ring; and between protein Pin1 and the sulfamate group.

### Claim 32 (depends on 30)

The method according to claim 30, for use in treating a condition in which modulating an activity of Pin1 is beneficial.

### Claim 33 (depends on 1)

A pharmaceutical composition comprising the Sulfamate compound according to claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 34 (depends on 1, 33)

A method of treating a disease or condition associated with Pin1 activity, comprising administering to a subject in need thereof the compound of claim 1, or a or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 33.

### Claim 35 (depends on 34)

The method of claim 34, wherein the disease or condition is a proliferative disease or disorder.

### Claim 36 (depends on 34)

The method of claim 34, wherein the disease is a cancer.

### Claim 37 (depends on 34)

The method of claim 34, wherein the disease is selected from the group consisting of a pancreatic cancer, a neuroblastoma, a prostate cancer, an ovarian carcinoma, and a breast adenocarcinoma.

### Claim 38 (depends on 34)

The method of claim 34, wherein the disease or condition is an immune disease or disorder.
